Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2157-2160

  Boletis, John N ^a   Marinaki, Smaragde ^a   Skalioti, Chryssanthe ^a   Lionaki, Sofia S ^a   Iniotaki, Aliki ^b   Sfikakis, Petros P ^c  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b Gennimatas Hospital   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CD20; Mycophenolate mofetil; Nephritis; Relapse; Rituximab; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; SERUM ALBUMIN;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RELAPSE; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; YOUNG ADULT;

EID: 67349230530     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp002     Document Type: Article

References (25)

1. Rahman A, Isenberg DA. Systemic lupus eryhthematosus. N Engl JMed 2008; 358: 929-939
2. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-121
3. Tsokos GC. Overview of cellular immune function in systemic lupus erythematosus. In: Lahita RG (ed.). Systemic Lupus Erythematosus, 2nd edn. New York: Churchill Livingstone, 1999, 17-54
4. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424
5. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. JAm Soc Nephrol 2004; 5: 241-250
6. Ioannidis JP, Boki KA, Katsorida ME et al. Remission, relapse and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 29: 258-264
7. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995-1002
8. El Hachmi M, Jadoul M, Lefebvre C et al. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696
9. Houssiau FA, Ginzler EM. Current therapies of lupus nephritis. Lupus 2008; 17: 426-430
10. Chan TM, Li FK, Tang CS et al. Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. NEnglJMed 2000; 343: 1156-1162
11. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
12. Chan TM, Tse KC, TangCSO et al. Hong-Kong Nephrology Study group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084
13. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
14. Schieppati A, Remuzzi G. Novel therapies of lupus nephritis. Curr Opin Nephrol Hypertens 2008; 17: 156-161
15. Sfikakis PP, Boletis J, Tsokos GC. Rituximab anti-B cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17: 550-557
16. Looney RJ, Anolik J, Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 2005; 8: 193-205
17. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513
18. Nwobi O, Abitbol CL, Chandar J et al. Rituximab therapy for juvenileonset systemic lupus erythematosus. Pediatr Nephrol 2008; 23: 423-429
19. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1995; 25: 1271-1277
20. Gunnarson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide- resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272
21. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590
22. Ahuja A, Shupe J, Dunn R et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007; 179: 3351-3361
23. Liossis SNC, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008; 127: 280-285
24. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83
25. Sfikakis PP, Souliotis VL, Fragiadaki KG et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007; 123: 66-73